Literature DB >> 23672534

The kinin-kallikrein system: physiological roles, pathophysiology and its relationship to cancer biomarkers.

Elena Kashuba1, James Bailey, David Allsup, Lynn Cawkwell.   

Abstract

The kinin-kallikrein system (KKS) is an endogenous multiprotein cascade, the activation of which leads to triggering of the intrinsic coagulation pathway and enzymatic hydrolysis of kininogens with the consequent release of bradykinin-related peptides. This system plays a crucial role in inflammation, vasodilation, smooth muscle contraction, cardioprotection, vascular permeability, blood pressure control, coagulation and pain. In this review, we will outline the physiology and pathophysiology of the KKS and also highlight the association of this system with carcinogenesis and cancer progression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23672534     DOI: 10.3109/1354750X.2013.787544

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  20 in total

1.  Kinins in Glioblastoma Microenvironment.

Authors:  Mona N Oliveira; Barbara Breznik; Micheli M Pillat; Ricardo L Pereira; Henning Ulrich; Tamara T Lah
Journal:  Cancer Microenviron       Date:  2019-08-16

Review 2.  Sex differences in carcinoid syndrome: A gap to be closed.

Authors:  Rosaria M Ruggeri; Barbara Altieri; Erika Grossrubatcher; Roberto Minotta; Maria Grazia Tarsitano; Virginia Zamponi; Andrea MIsidori; Antongiulio Faggiano; Anna Maria Colao
Journal:  Rev Endocr Metab Disord       Date:  2022-03-16       Impact factor: 6.514

3.  Bradykinin release avoids high molecular weight kininogen endocytosis.

Authors:  Igor Z Damasceno; Katia R B Melo; Fabio D Nascimento; Daianne S P Souza; Mariana S Araujo; Sinval E G Souza; Misako U Sampaio; Helena B Nader; Ivarne L S Tersariol; Guacyara Motta
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

4.  Biomarkers of systemic inflammation in farmers with musculoskeletal disorders; a plasma proteomic study.

Authors:  Bijar Ghafouri; Anders Carlsson; Sara Holmberg; Anders Thelin; Christer Tagesson
Journal:  BMC Musculoskelet Disord       Date:  2016-05-10       Impact factor: 2.362

5.  Kinin-B1 Receptor Stimulation Promotes Invasion and is Involved in Cell-Cell Interaction of Co-Cultured Glioblastoma and Mesenchymal Stem Cells.

Authors:  Mona N Oliveira; Micheli M Pillat; Helena Motaln; Henning Ulrich; Tamara T Lah
Journal:  Sci Rep       Date:  2018-01-22       Impact factor: 4.379

Review 6.  Medicinal leech therapy-an overall perspective.

Authors:  Ali K Sig; Mustafa Guney; Aylin Uskudar Guclu; Erkan Ozmen
Journal:  Integr Med Res       Date:  2017-08-10

Review 7.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

8.  Kininase 1 As a Preclinical Therapeutic Target for Kinin B1 Receptor in Insulin Resistance.

Authors:  Youssef Haddad; Réjean Couture
Journal:  Front Pharmacol       Date:  2017-08-02       Impact factor: 5.810

9.  Altered apolipoprotein C expression in association with cognition impairments and hippocampus volume in schizophrenia and bipolar disorder.

Authors:  Christian Knöchel; Jonathan Kniep; Jason D Cooper; Michael Stäblein; Sofia Wenzler; Jan Sarlon; David Prvulovic; David E J Linden; Sabine Bahn; Pawel Stocki; Sureyya Ozcan; Gilberto Alves; Andre F Carvalho; Andreas Reif; Viola Oertel-Knöchel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-22       Impact factor: 5.270

10.  The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model.

Authors:  Patricia Luiza Nunes da Costa; David Wynne; Theodora Fifis; Linh Nguyen; Marcos Perini; Christopher Christophi
Journal:  BMC Cancer       Date:  2018-04-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.